BB Biotech Ventures
VC Fund
Zürich, Switzerland
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated teamof investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 9%
- Fund size:
- $96M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BB Biotech Ventures invests in
Stages BB Biotech Ventures invests in
Countries BB Biotech Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.1M–$24M
- Series B
- $9M–$132M
- Series C
- $3.3M–$66M
Investment Focus
Industry
- Biotechnology 21 (60%)
- Health Care 14 (40%)
- Medical 10 (29%)
- Pharmaceutical 10 (29%)
- Therapeutics 6 (17%)
Stage
- Series C 8 (23%)
- Series A 5 (14%)
- Series B 4 (11%)
- Series D 4 (11%)
- Series E 2 (6%)
Country
- United States 13 (37%)
- Switzerland 5 (14%)
- Italy 1 (3%)
- Germany 1 (3%)
- Ireland 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Martin Münchbach
Managing Director
|
Managing Director | Total investments: 12 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Molecular Templates is a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases. It primarily develops a pipeline of therapies through its proprietary biologic-engineered toxin body (ETB) drug platform with unique mechanisms of action which are highly differentiated from antibody-drugconjugates (ADCs). | $9.5M / Post-IPO Equity / Mar 28, 2024 | ||
| Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. | $350M / Post-IPO Equity / Nov 27, 2023 | ||
| Molecular Templates is a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases. It primarily develops a pipeline of therapies through its proprietary biologic-engineered toxin body (ETB) drug platform with unique mechanisms of action which are highly differentiated from antibody-drugconjugates (ADCs). | $40M / Post-IPO Equity / Jul 13, 2023 | ||
| Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity. | $132M / Series B / Sep 22, 2022 | ||
| AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands. | $25.4M / Venture - Series Unknown / Mar 31, 2020 | ||
| Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified. | $8.1M / Series E / Dec 16, 2019 | ||
| Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck. | $500M / Series G / Feb 01, 2018 | ||
| Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $35M / Series D / Jan 23, 2017 | ||
| Abyrx acquisition of the HEMASORB Resorbable Hemostatic Bone Putty portfolio and the right to develop Bezwada Biomedical’s polymer technology for bone applications. The Company develops, manufactures, and provides therapeutic devices for use during surgical procedures. | $10M / Venture - Series Unknown / Dec 06, 2016 | ||
| Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified. | $18M / Series C / May 27, 2016 | ||
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does BB Biotech Ventures invest in?
BB Biotech Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Series A stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BB Biotech Ventures's check size?
BB Biotech Ventures typically joins rounds of $1.1M–$24M at Series A, $9M–$132M at Series B and $3.3M–$66M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BB Biotech Ventures participates in.
How do I contact BB Biotech Ventures?
Public channels for BB Biotech Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BB Biotech Ventures?
The team at BB Biotech Ventures includes Martin Münchbach (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
